Major RSV vaccine trial for seniors nears completion

NCT ID NCT05035212

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study tests whether a single dose of Pfizer's RSV vaccine (RSVpreF) can prevent lower respiratory tract illness caused by RSV in adults aged 60 and older. Over 38,800 participants across multiple countries received either the vaccine or a placebo. The study also looks at safety and whether a booster dose given 1-4 years later remains effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: RSV vaccine (RSVpreF)
What this could lead to: If successful, this could lead to a new vaccine that protects older adults from serious RSV-related lung infections.
What could go wrong: This is a large Phase 3 trial, but vaccines can fail or show only modest benefit. Side effects like injection-site pain or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

38,861 people

The number who actually took part.

Started

Aug 2021

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Efficacy Study Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration. * Female participants must not be of childbearing potential. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 3). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. Substudy A Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration. * Female participants must not be of childbearing potential. * Participants who received RSVpreF in the efficacy study. * Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 103). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study \- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy A. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Participant was confirmed by the sponsor to have previously received the study intervention more than once. Substudy B Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration. * Female participants must not be of childbearing potential. 6. Participants who received RSVpreF in the efficacy study. * Participants who received RSVpreF in the efficacy study. * Participants who have a Visit 2 serology sample available for testing from the efficacy study and did not meet exclusion criteria through Visit 4 of the efficacy study. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 203). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy B. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Participant was confirmed by the sponsor to have previously received the study intervention more than once. * Participants who completed Vaccination 1 from the efficacy study less than 9 months or greater than 15 months prior to revaccination. Substudy C Inclusion Criteria: * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, when indicated. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol. * Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. * Male or female participants ≥60 years of age. * Participants who received RSVpreF in the efficacy study. * Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration. Exclusion Criteria: * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine. * Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 303 or Visit 306). Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study \- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone. * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy C. * Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Participant was confirmed by the sponsor to have previously received the study intervention more than once. * Prior history of any subtype of Guillain-Barré syndrome of any etiology. * Current or prior participation in Substudy A or Substudy B. * Participants who completed Vaccination 1 from the efficacy study less than 32 months or greater than 40 months prior to revaccination.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lower respiratory tract disorder respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lower respiratory tract illness

Contacts and locations

Locations

AMC Nishiumeda Clinic

Osaka, 530-0001, Japan
AMR Clinical

Lexington, Kentucky, 40509, United States
AMR Clinical

Knoxville, Tennessee, 37909, United States
About Allergy

Pretoria, Gauteng, 0181, South Africa
Accellacare - Charlotte

Charlotte, North Carolina, 28211, United States
Accellacare - DuPage

Oak Lawn, Illinois, 60453, United States
Accellacare - Wilmington

Wilmington, North Carolina, 28401, United States
Accellacare - Wilmington - 1917 Tradd Court

Wilmington, North Carolina, 28401, United States
Accellacare US Inc., d/b/a Accellacare of Knoxville

Knoxville, Tennessee, 37912, United States
ActivMed Practices & Research, LLC

Beverly, Massachusetts, 01915, United States
ActivMed Practices & Research, LLC

Methuen, Massachusetts, 01844, United States
ActivMed Practices and Research, LLC.

Portsmouth, New Hampshire, 03801, United States
Advance Medical Research Center

Miami, Florida, 33135, United States
Affinity Health Corp

Oak Brook, Illinois, 60523, United States
Aggarwal and Associates Limited

Brampton, Ontario, L6T 0G1, Canada
Allegiance Research Specialists, LLC

Wauwatosa, Wisconsin, 53226, United States
Alliance for Multispecialty Research, LLC

Tempe, Arizona, 85281, United States
Alliance for Multispecialty Research, LLC

Las Vegas, Nevada, 89119, United States
Allure Health at Mt. Olympus Medical Research

Friendswood, Texas, 77546, United States
Alpha Recherche Clinique

Québec, Quebec, G2J 0C4, Canada
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

Troy, Michigan, 48098, United States
Ark Clinical Research

Long Beach, California, 90815, United States
Artemis Institute for Clinical Research

Riverside, California, 92503, United States
Artemis Institute for Clinical Research

San Diego, California, 92123, United States
Ascension St. John Hospital Vaccine Research Unit

Grosse Pointe Woods, Michigan, 48236, United States
Atrium Health - Strive Vaccine Research Clinic

Charlotte, North Carolina, 28207, United States
Be Part Yoluntu Centre

Paarl, Western Cape, 7626, South Africa
Benchmark Research

Colton, California, 92324, United States
Benchmark Research

Sacramento, California, 95864, United States
Benchmark Research

Austin, Texas, 78705, United States
Benchmark Research

Fort Worth, Texas, 76135, United States
Botho Ke Bontle Health Services

Pretoria, 0184, South Africa
CHEAR Center LLC

The Bronx, New York, 10455, United States
California Research Foundation

San Diego, California, 92123, United States
Capital Area Research, LLC

Camp Hill, Pennsylvania, 17011, United States
Centex Studies

Houston, Texas, 77058, United States
Centex Studies

Houston, Texas, 77090, United States
Central Erie Primary Care

Erie, Pennsylvania, 16508, United States
Central Washington Health Services Association d/b/a Confluence Health

Wenatchee, Washington, 98801, United States
Centre de Recherche Saint-Louis inc.

Québec, G1W 4R4, Canada
Centricity Research Columbus Ohio Multispecialty

Columbus, Ohio, 43213, United States
Centricity Research Mirabel Multispecialty

Mirabel, Quebec, J7J 2K8, Canada
Centricity Research Suffolk Primary Care

Suffolk, Virginia, 23435, United States
Centricity Research Toronto LMC Multispecialty

Toronto, Ontario, M4G 3E8, Canada
Centricity Research Toronto Manna Multispecialty

Toronto, Ontario, M9W 4L6, Canada
Chemidox Clinical Trials

Lancaster, California, 93534, United States
Clinica Mayo de Urgencias Medicas Cruz Blanca S.R.L

San Miguel de Tucumán, Tucumán Province, 4000, Argentina
Clinica Privada Instituto Medico Platense S.A.

La Plata, Buenos Aires, B1900AVG, Argentina
Clinica Privada del Sol S.A.

Córdoba, 5000, Argentina
Clinica mi Salud by Focil Med

Oxnard, California, 93030, United States
Clinical Research Associates, Inc.

Nashville, Tennessee, 37203, United States
Clinical Research Atlanta

Stockbridge, Georgia, 30281, United States
Clinical Research Consulting

Milford, Connecticut, 06460, United States
Clinical Research Hospital Tokyo

Shinjuku-ku, Tokyo, 160-0004, Japan
Clinical Research Hospital Tokyo

Shinjuku-ku, Tokyo, 162-0053, Japan
Clinical Site Partners, LLC dba Flourish Research

Winter Park, Florida, 32789, United States
Clinical Trials of Texas, LLC

San Antonio, Texas, 78229, United States
Clinical Trials of Texas, LLC dba Flourish Research

San Antonio, Texas, 78229, United States
Clinique de Médecine Urbaine du Quartier Latin

Montreal, Quebec, H2L 4E9, Canada
Coastal Heritage Clinical Research

Hinesville, Georgia, 31313, United States
Cognitive Clinical Trials, LLC

Phoenix, Arizona, 85044, United States
Conquest Research

Winter Park, Florida, 32789, United States
Corning Center for Clinical Research

Horseheads, New York, 14845, United States
DBC Research USA

Pembroke Pines, Florida, 33029, United States
DM Clinical Research

Melrose Park, Illinois, 60160, United States
DM Clinical Research - Bellaire

Houston, Texas, 77081, United States
DM Clinical Research - Cy Fair

Houston, Texas, 77065, United States
DM Clinical Research - Humble

Humble, Texas, 77338, United States
DM Clinical Research, Martin Diagnostic Clinic

Humble, Texas, 77338, United States
DM Clinical Research- Cyfair

Houston, Texas, 77065, United States
Dawson Clinical Research Inc

Guelph, Ontario, N1H 1B1, Canada
De La Cruz Research Center, LLC

Miami, Florida, 33184, United States
De Silva Medical Inc

Palmdale, California, 93551, United States
Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States
Diex Recherche Inc. Division Victoriaville

Victoriaville, Quebec, G6P 3Z8, Canada
Diex Recherche Quebec

Québec, G1V 4T3, Canada
Diex Recherche Sherbrooke

Sherbrooke, Quebec, J1L 0H8, Canada
Doral Medical Research, LLC

Hialeah, Florida, 33016, United States
Downtown L.A. Research Center, Inc.

Los Angeles, California, 90017, United States
Dr A Jacovides & Partners Inc.

Midrand, Gauteng, 1685, South Africa
Dr. Anil K. Gupta Medicine Professional Corporation

Toronto, Ontario, M9V 4B4, Canada
Drug Trials America

Hartsdale, New York, 10530, United States
Dynamed Clinical Research, LP d/b/a DM Clinical Research

Sugar Land, Texas, 77478, United States
Dynamed Clinical Research, LP d/b/a DM Clinical Research

Tomball, Texas, 77375, United States
Emmed Research

Pretoria, 0002, South Africa
Empire Clinical Research

Pomona, California, 91767, United States
Espoo Vaccine Research Clinic

Espoo, 02230, Finland
FCRN Clinical Trial Centre

Vereeniging, Gauteng, 1935, South Africa
FVR, Etelä-Helsingin rokotetutkimusklinikka

Helsinki, 00100, Finland
Flourish Research - Miami, LLC

Miami, Florida, 33135, United States
Franciscus Gasthuis & Vlietland, location Gasthuis

Rotterdam, 3045 PM, Netherlands
Fukuwa Clinic

Chuo-ku, Tokyo, 104-0031, Japan
Fundación Respirar

CABA, Buenos Aires, C1426ABP, Argentina
Gezondheidscentrum Leonardus

Helmond, 5701 AH, Netherlands
Global Clinical Trials

Pretoria, Gauteng, 0083, South Africa
Global Health Research Center, Inc.

Miami Lakes, Florida, 33016, United States
Great Lakes Clinical Trials, LLC dba Flourish Research

Chicago, Illinois, 60640, United States
HG Pediatrics

Houston, Texas, 77008, United States
HOPE Research Institute

Phoenix, Arizona, 85018, United States
HOPE Research Institute

Phoenix, Arizona, 85023, United States
HOPE Research Institute

Tempe, Arizona, 85284, United States
Hany H. Ahmed, MD

Houston, Texas, 77008, United States
Headlands Research - Scottsdale

Scottsdale, Arizona, 85260, United States
Headlands Research Orlando

Orlando, Florida, 32819, United States
Headlands Research Sarasota

Sarasota, Florida, 34243, United States
Helderberg Clinical Trials Centre

Somerset West, Western Cape, 7129, South Africa
Helios Clinical Research - HOU

Houston, Texas, 77008, United States
Helsinki East Vaccine Research Clinic

Helsinki, 00930, Finland
Hillside Clinic Jingumae

Shibuya-ku, Tokyo, 1500001, Japan
Hope Clinical Research

Canoga Park, California, 91303, United States
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich

CABA, Buenos Aires, 1426, Argentina
Hospital de Clinicas Presidente Nicolas Avellaneda

San Miguel de Tucumán, Tucumán Province, 4000, Argentina
Huisartsen Soest

Soest, 3762BN, Netherlands
Huisartsencentrum Parklaan

Eindhoven, 5613 BE, Netherlands
Huisartsenpraktijk Radesingel

Groningen, 9718 TA, Netherlands
IDEAL Clinical Research

Aventura, Florida, 33180, United States
IDEAL Clinical Research

Pembroke Pines, Florida, 33026, United States
IMA Clinical Research Warren

Warren Township, New Jersey, 07059, United States
IMAC - Instituto Medico de Alta Complejidad

Salta, 4400, Argentina
Indago Research & Health Center, Inc

Hialeah, Florida, 33012, United States
Innovative Research of West Florida

Clearwater, Florida, 33756, United States
Innovo Research - Austin Regional Clinic

Austin, Texas, 78726, United States
Instituto De Investigaciones Clínicas Mar Del Plata

Mar del Plata, Buenos Aires, B7600FZO, Argentina
Into Research

Pretoria, Gauteng, 0181, South Africa
Invictus Clinical Research Group, LLC

Coconut Creek, Florida, 33073, United States
J. Lewis Research, Inc. / Foothill Family Clinic Draper

Draper, Utah, 84020, United States
J. Lewis Research, Inc. / Jordan River Family Medicine

South Jordan, Utah, 84095, United States
JEM Research Institute

Atlantis, Florida, 33462, United States
Javara - Privia Medical Group Georgia - Albany

Albany, Georgia, 31707, United States
Javara - Privia Medical Group Georgia - Savannah

Savannah, Georgia, 31406, United States
Javara - Privia Medical Group Gulf Coast - The Woodlands HWH

Conroe, Texas, 77384, United States
Javara Inc.

Thomasville, Georgia, 31792, United States
Javara Inc.

Sugar Land, Texas, 77478, United States
Jongaie Research

Pretoria, Gauteng, 0183, South Africa
Josha Research

Bloemfontein, Free State, 9301, South Africa
Julius Clinical Breda

Zeist, 3703 CD, Netherlands
Järvenpää Vaccine Research Clinic

Jarvenpaa, 04400, Finland
Kaiser Permanente Northwest Center for Health Research

Portland, Oregon, 97227, United States
Kaye Edmonton Clinic

Edmonton, Alberta, T6G 1Z1, Canada
Kokkola Vaccine Research Clinic

Kokkola, 67100, Finland
Las Vegas Clinical Trials

North Las Vegas, Nevada, 89030, United States
Lenzmeier Family Medicine / Avacare

Glendale, Arizona, 85308, United States
Lynn Institute of Denver

Aurora, Colorado, 80012, United States
M3 Wake Research - Lake City

Lake City, Florida, 32055, United States
MERC Research (Pty) Ltd - Middelburg

Middelburg, Mpumalanga, 1055, South Africa
MERCLINCO (Pty) Ltd - Kempton

Kempton Park, Gauteng, 1619, South Africa
MOC Research

Mishawaka, Indiana, 46544, United States
Marvel Clinical Research 002, LLC

Huntington Beach, California, 92647, United States
Meander Medisch Centrum

Amersfoort, 3813 TZ, Netherlands
Medical Affiliated Research Center

Huntsville, Alabama, 35801, United States
Medical Corp. Seikoukai New Medical Research System Clinic

Hachioji-shi, Tokyo, 192-0046, Japan
Medical Corporation Heishinkai OPHAC Hospital

Osaka, Osaka, 532-0003, Japan
Meridian Clinical Research, LLC

Sioux City, Iowa, 51106, United States
Michigan Center of Medical Research (MICHMER)

Farmington Hills, Michigan, 48334, United States
Milton Haber, M.D.

Laredo, Texas, 78041, United States
Milton Haber, MD

Laredo, Texas, 78041, United States
Motomachi Takatsuka Naika Clinic

Yokohama, Kanagawa, 231-0023, Japan
Mt Olympus Medical Research

Sugar Land, Texas, 77479, United States
MultiCare Institute for Research & Innovation

Tacoma, Washington, 98405, United States
MultiCare Medical Group

Tacoma, Washington, 98405, United States
Nature Coast Clinical Research

Crystal River, Florida, 34429, United States
New Horizon Research Center

Miami, Florida, 33165, United States
Newtown Clinical Research Centre (PTY) LTD

Newtown, Gauteng, 2001, South Africa
Next Phase Research Alliance

Miami, Florida, 33144, United States
Nihonbashi Sakura Clinic

Chuo-ku, Tokyo, 103-0025, Japan
Noble Clinical Research

Tucson, Arizona, 85704, United States
North Texas Infectious Diseases Consultants, P.A

Dallas, Texas, 75246, United States
Northwest Clinical Research Center

Bellevue, Washington, 98007, United States
Oakland Medical Research

Troy, Michigan, 48085, United States
Ochsner Clinic Foundation

Kenner, Louisiana, 70065, United States
Ochsner Medical Center - Kenner

Kenner, Louisiana, 70065, United States
Oda Clinic

Shinjuku-ku, Tokyo, 169-0072, Japan
Optimus U Corporation

Miami, Florida, 33125, United States
Optimus U Corporation

Miami, Florida, 33135, United States
Oulu Vaccine Research Clinic

Oulu, 90220, Finland
Paradigm Clinical Research Center

Redding, California, 96001, United States
Penn Prevention Unit

Philadelphia, Pennsylvania, 19104, United States
Phoenix Clinical LLC

Phoenix, Arizona, 85014, United States
Pines Care Research Center, LLC

Pembroke Pines, Florida, 33024, United States
PoliDirect Amsterdam West

Amsterdam, 1064 BP, Netherlands
PoliDirect Nieuwegein

Nieuwegein, 3431 HR, Netherlands
Pori Vaccine Research Clinic

Pori, 28100, Finland
Precision Clinical Research

Sunrise, Florida, 33351, United States
Premier Clinical Trial Network

Hamilton, Ontario, L8L 5G4, Canada
Quality Clinical Research

Omaha, Nebraska, 68114, United States
Research Building

Wenatchee, Washington, 98801, United States
Rochester Clinical Research, LLC

Rochester, New York, 14609, United States
SMS Clinical Research

Mesquite, Texas, 75149, United States
SOUSEIKAI PS Clinic

Fukuoka, 812-0025, Japan
Saint Louis University

St Louis, Missouri, 63104, United States
Sasaki Clinic

Amagasaki, Hyōgo, 660-0827, Japan
Seinäjoki Vaccine Research Clinic

Seinäjoki, 60100, Finland
Seishinkai Inoue Hospital

Itoshima, Fukuoka, 819-1104, Japan
Sekino Hospital

Toshima-ku, Tokyo, 171-0014, Japan
Sensenbrenner Primary Care Research Office

Charlotte, North Carolina, 28277, United States
Setshaba Research Centre

Soshanguve, Gauteng, 0152, South Africa
Skyline Medical Center, PC/CCT Research

Elkhorn, Nebraska, 68022, United States
Snake River Research, PLLC

Idaho Falls, Idaho, 83404, United States
Solaris Clinical Research

Meridian, Idaho, 83646, United States
Sound Medical Research

Port Orchard, Washington, 98366, United States
Souseikai Sumida Hospital

Sumida-ku, Tokyo, 130-0004, Japan
South Jersey Infectious Disease

Somers Point, New Jersey, 08244, United States
Spaarne Gasthuis

Hoofddorp, 2134 TM, Netherlands
St. Vincent's Birmingham

Birmingham, Alabama, 35205, United States
St. Vincent's Birmingham (Pharmacy)

Birmingham, Alabama, 35205, United States
Stamford Therapeutics Consortium

Stamford, Connecticut, 06905, United States
Sugiura Clinic

Kawaguchi, Saitama, 332-0012, Japan
Summit Headlands, LLC

Portland, Oregon, 97210, United States
Sun Research Institute

San Antonio, Texas, 78215, United States
Sundance Clinical Research

St Louis, Missouri, 63141, United States
Synexus - Helderberg Clinical Research Centre - Somerset West

Cape Town, Western Cape, 7130, South Africa
Synexus SA- Watermeyer Clinical Research Center

Pretoria, Gauteng, 0184, South Africa
TREAD Research

Cape Town, Western Cape, 7500, South Africa
Tampere Vaccine Research Clinic

Tampere, 33100, Finland
Tanner Clinic

Layton, Utah, 84041, United States
Tekton Research LLC

Longmont, Colorado, 80501, United States
Tekton Research, Inc

Yukon, Oklahoma, 73099, United States
Tekton Research, LLC.

Edmond, Oklahoma, 73013, United States
Tekton Research, LLC.

Austin, Texas, 78745, United States
Tekton Research, LLC.

Beaumont, Texas, 77706, United States
Tenjin General Clinic

Fukuoka, Fukuoka, 810-0021, Japan
Terveystalo Jyväskylä

Jyväskylä, 40100, Finland
Terveystalo Tampere

Tampere, 33100, Finland
Terveystalo Turku Pulssi

Turku, 20100, Finland
Texas Health Family Care

Fort Worth, Texas, 76135, United States
The Corvallis Clinic, PC

Corvallis, Oregon, 97330, United States
The Institute for Liver Health dba Arizona Clinical Trials

Tucson, Arizona, 85712, United States
The Pain Center of Arizona

Phoenix, Arizona, 85018, United States
Tokyo Asbo Clinic

Chuo-ku, Tokyo, 104-0031, Japan
Tokyo Eki Center Building Clinic

Chuo-ku, Tokyo, 103-0027, Japan
Trio Clinical Trials, LLC

Houston, Texas, 77008, United States
Tryon Medical Partners, PLLC

Charlotte, North Carolina, 28210, United States
Turku Vaccine Research Clinic

Turku, 20520, Finland
UMC Utrecht

Utrecht, 3584 CX, Netherlands
Universal Axon Clinical Research, LLC (Administrative)

Doral, Florida, 33166, United States
University Of Alberta Hospital

Edmonton, Alberta, T6G 2B7, Canada
University of Iowa

Iowa City, Iowa, 52242, United States
University of Massachusetts Chan Medical School

Worcester, Massachusetts, 01655, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
Van Tran Family Practice

Houston, Texas, 77008, United States
Velocity Clinical Research - Cincinnati

Cincinnati, Ohio, 45242, United States
Velocity Clinical Research Valparaiso

Valparaiso, Indiana, 46383, United States
Velocity Clinical Research, Binghamton

Binghamton, New York, 13905, United States
Velocity Clinical Research, Cincinnati, Mt. Auburn

Cincinnati, Ohio, 45219, United States
Velocity Clinical Research, Grants Pass

Grants Pass, Oregon, 97527, United States
Velocity Clinical Research, Medford

Medford, Oregon, 97504, United States
Velocity Clinical Research, Metairie

Metairie, Louisiana, 70006, United States
Velocity Clinical Research, North Hollywood

North Hollywood, California, 91606, United States
Velocity Clinical Research, Providence

East Greenwich, Rhode Island, 02818, United States
Velocity Clinical Research, Rockville

Rockville, Maryland, 20854, United States
Velocity Clinical Research, Salt Lake City

West Jordan, Utah, 84088, United States
Velocity Clinical Research, Savannah

Savannah, Georgia, 31406, United States
Velocity Clinical Research, Springdale

Cincinnati, Ohio, 45246, United States
Velocity Clinical Research, Vestal

Vestal, New York, 13850, United States
Ventavia Research Group, LLC

Houston, Texas, 77008, United States
Virginia Gastroenterology Clinical Research

Suffolk, Virginia, 23435, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States
Welkom Clinical Trial Centre (MERC WELKOM)

Welkom, Free State, 9460, South Africa
West Coast Research

Dublin, California, 94568, United States
Wits Vaccines & Infectious Diseases Analytics

Soweto, Gauteng, 2195, South Africa
Worthwhile Clinical Trials

Benoni, Gauteng, 1500, South Africa
Wr-Crcn, Llc.

Las Vegas, Nevada, 89106, United States
eStudySite

Chula Vista, California, 91911, United States